Rallybio has stopped being a rare-disease developer and has become a listed cash box that is handing its Nasdaq registration to a private oncology company. The May break-up of the Candid combination dropped a $50 million termination fee onto the balance sheet, and the board signed a reverse merger with Avenzo Therapeutics that leaves legacy holders with just under three percent of the combined firm. What remains for today's shareholders is a pre-close cash distribution, a thin residual stub, and a contingent value right on leftover programs. The equity is now a deal, not a pipeline.
The second-quarter print looks profitable only because that fee landed in other income. Underlying operations still lost money, even after research spending collapsed following the RLYB212 shutdown and the wind-down of internal development. Cash at mid-year sat near $93 million against a market value of about $91 million, which is the market saying the listing, the stub, and the contingent claim are worth little once the cash leaves. The live debate is whether closing-date net cash holds near the mid-August estimate of $82 million or leaks through advisory costs, taxes, and residual operating spend.
Avenzo contributes four early clinical oncology programs and a committed private placement of $215 million. Combined-company math assigns $300 million to Avenzo equity and $15 million to the emptied Rallybio stub. Legacy holders also receive one contingent value right per share tied to any sale of leftover programs and to remaining Recursion payments. The question the next several months resolve is whether the reverse merger closes with a clean cash distribution, or whether the listing sits as an orphaned remnant with shrinking cash and no partner.